ABBV: Approves SKYRIZI for Pediatric Psoriasis
AbbVie announces European Commission approval of SKYRIZI for treating pediatric patients with moderate to severe plaque psoriasis
ABBV - AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis